In another small clinical trial investigating the clinical activity of the anti-CTLA4 antibody Ipilimumab in patients with synovial sarcoma expressing NY-ESO-1 antigens, only 1 of the 6 patients showed remission (31). This evidence concerns the gene CTLA4 and synovial sarcoma.